Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
IPO Year:
Exchange: NYSE
Website: stryker.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2026 | $410.00 | Outperform | Leerink Partners |
| 2/20/2026 | Outperform | William Blair | |
| 1/27/2026 | $387.00 | Hold | TD Cowen |
| 1/6/2026 | $418.00 | Mkt Perform → Outperform | Raymond James |
| 12/19/2025 | $440.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 9/18/2025 | $420.00 | Neutral | Rothschild & Co Redburn |
| 2/26/2025 | $450.00 | Buy | Citigroup |
| 12/2/2024 | $370.00 → $445.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/10/2024 | $405.00 | Outperform | Wolfe Research |
| 5/30/2024 | $372.00 | Neutral | Goldman |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
Fastest customizable press release news feed in the world
PORTAGE, Mich., June 2, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its TPX HD, a premium small bone power tool designed to support performance, control and ergonomics in a wide range of challenging orthopaedic procedures such as total joint revisions, minimally invasive surgery and oral maxillofacial procedures. "Revision procedures are some of the most demanding cases surgeons face, especially when metal cutting is involved," said Mike Carlin, president of Stryker's Ortho Tech division. "TPX HD was designed with tho
Stryker (NYSE:SYK), a global leader in medical technologies, announced today the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns. Prof. Alex Trompeter, design surgeon and orthopaedic trauma surgeon, along with his team at St. George's University Hospital in London, completed the first clinical case in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525326817/en/Stryker's Pangea Plating System brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures. "Pan
Three companies with strong roots in the state are revolutionizing the treatment of cardiovascular disease through hydraulic lithotripsy technology BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in the expansion of its peripheral vascular portfolio. All three companies have close t
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. "This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease," said Kevin Lobo, Chair and CEO, Stryker. "By integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources, we are well-positioned to deliver solutions that support p
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 m
Portage, Michigan, May 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Spencer Stiles, President and Chief Operating Officer, Jason Beach, Vice President, Group Chief Financial Officer, MedSurg and Neurotechnology and Nick Mead, Vice President, Investor Relations. Their presentation is scheduled for 1:40 p.m. Pacific Time. A live webcast and replay of the presentation will be accessible on Stryker's website at www.stryker.com, and it will be archived on the Investor Relations page. About Stryke
Portage, Michigan, April 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2026: First Quarter Results Reported net sales increased 2.6% to $6.0 billionOrganic net sales increased 2.4%Reported operating income margin of 15.5%Adjusted operating income margin(1) contracted 180 bps to 21.1%Reported EPS increased 14.2% to $1.93 Adjusted EPS(1) decreased 8.5% to $2.60 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 5.0 % 1.4 % 3.6 % 2.7 % 0.9 %Orthopaedics
PHILADELPHIA, April 24, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC advises shareholders of Stryker Corporation (NYSE:SYK) ("Stryker" or the "Company") about an investigation into Stryker's Board of Directors (the "Board") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation focuses on whether the Board failed to exercise appropriate oversight regarding its cybersecurity and data protection practices, including the Company's response to a recent cyber incident affecting its operations and data environment. Shareholders of Stryker may learn more about this investigation by contacting Berger Montague: Andrew Abr
PHILADELPHIA, April 16, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC advises shareholders of Stryker Corporation (NYSE:SYK) ("Stryker" or the "Company") about an investigation into Stryker's Board of Directors (the "Board") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation focuses on whether the Board failed to exercise appropriate oversight regarding its cybersecurity and data protection practices, including the Company's response to a recent cyber incident affecting its operations and data environment.
Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease. The acquisition will strengthen Stryker's Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker's existing PV offerings and support the company's strategy to expand its presence in arterial disease treatment
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Leerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00
William Blair initiated coverage of Stryker with a rating of Outperform
TD Cowen resumed coverage of Stryker with a rating of Hold and set a new price target of $387.00
Raymond James upgraded Stryker from Mkt Perform to Outperform and set a new price target of $418.00
Citizens JMP upgraded Stryker from Mkt Perform to Mkt Outperform and set a new price target of $440.00
Rothschild & Co Redburn initiated coverage of Stryker with a rating of Neutral and set a new price target of $420.00
Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00
Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously
Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
SD - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
10-Q - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
8-K/A - STRYKER CORP (0000310764) (Filer)
SCHEDULE 13G/A - STRYKER CORP (0000310764) (Subject)
DEFA14A - STRYKER CORP (0000310764) (Filer)
DEF 14A - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
Live Leadership Updates
GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s
Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy
Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
EMERYVILLE, Calif., Sept. 12, 2024 /PRNewswire/ -- Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, today announced the appointment of Brent D. Lang, former Chairman and CEO of Vocera Communications, to its Board of Directors. Lang brings over three decades of healthcare and technology experience, having led Vocera through rapid growth, a successful IPO, and its $3 billion acquisition by Stryker (NYSE:SYK). His strategic vision and proven leadership will guide Eko as it continues to innovate and expand its platform
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
Live finance-specific insights
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. "This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease," said Kevin Lobo, Chair and CEO, Stryker. "By integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources, we are well-positioned to deliver solutions that support p
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 m
Portage, Michigan, April 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2026: First Quarter Results Reported net sales increased 2.6% to $6.0 billionOrganic net sales increased 2.4%Reported operating income margin of 15.5%Adjusted operating income margin(1) contracted 180 bps to 21.1%Reported EPS increased 14.2% to $1.93 Adjusted EPS(1) decreased 8.5% to $2.60 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 5.0 % 1.4 % 3.6 % 2.7 % 0.9 %Orthopaedics
Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 15
Portage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2025: Fourth Quarter Results Reported net sales increased 11.4% to $7.2 billionOrganic net sales increased 11.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 100 bps to 30.2%Reported EPS increased 56.0% to $2.20Adjusted EPS(1) increased 11.5% to $4.47 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 17.5 % 0.9 % 16.6 % 4.0 % 12.6 %
Deal expands global manufacturing footprint and positions VB Spine for future growth in spine care VB Spine LLC ("VB Spine") today completed the acquisition of Stryker's spine implant manufacturing facility in Cestas, France. Known for its state-of-the-art operations and technical capabilities, the Cestas facility will play a central role in VB Spine's global manufacturing strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106463289/en/VB Spine's manufacturing facility in Cestas, France This milestone expands on the April 1, 2025 formation of VB Spine, established through the acquisition of Stryker's U.S. spine implan
Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter. "We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are drive
Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billionOrganic net sales increased 9.5%Reported operating income margin of 18.7%Adjusted operating income margin(1) increased 90 bps to 25.6%Reported EPS increased 2.8% to $2.22Adjusted EPS(1) increased 11.1% to $3.19 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 14.4 % 0.5 % 13.9 % 5.5 % 8.4 %Orthopaedics 3
Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more
Portage, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2025: Second Quarter Results Reported net sales increased 11.1% to $6.0 billionOrganic net sales increased 10.2%Reported operating income margin of 18.5%Adjusted operating income margin(1) increased 110 bps to 25.7%Reported EPS increased 7.0% to $2.29Adjusted EPS(1) increased 11.4% to $3.13 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 17.3 % 0.6 % 16.7 % 5.7 % 11.0 %Orthopaedics
This live feed shows all institutional transactions in real time.
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)